<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02757417</url>
  </required_header>
  <id_info>
    <org_study_id>UHcaseMC1</org_study_id>
    <nct_id>NCT02757417</nct_id>
  </id_info>
  <brief_title>Intravenous Sodium Fluorescein Versus Oral Phenazopyridine for Ureteral Patency</brief_title>
  <official_title>A Randomized Trial Comparing Intaoperative Intravenous Sodium Fluorescein to Pre-Operative Oral Phenazopyridine For Evaluation of Ureteral Patency</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospitals Cleveland Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Megan Billow</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Graham Chapman</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Sangeeta Mahajan</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Alex Soriano</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Sherif El-Nashar</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospitals Cleveland Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To determine the safety profile of sodium fluorescein in women undergoing cystoscopy during
      gynecologic surgery. To determine if either oral phenazopyridine or sodium fluorescein result
      in shorter cystoscopy times.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 2016</start_date>
  <completion_date type="Anticipated">December 2019</completion_date>
  <primary_completion_date type="Anticipated">January 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>differences in time that elapses between starting cystoscopy and identifying both ureteral jets between treatment groups</measure>
    <time_frame>12 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>number of participants with intra-operative and immediate and post-operative treatment-related adverse events as assessed by CTCAE v4.0</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">88</enrollment>
  <condition>Ureteral Injury</condition>
  <arm_group>
    <arm_group_label>Sodium Fluorescein</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients will receive an intravenous dose of 0.25 mL of 10% (500 mg, 5 mL) sodium fluorescein at the time of cystoscope insertion, for a total dose of 25 mg. Cystoscopy will be performed in the standard fashion during the course of the operation.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>oral phenazopyridine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients randomized to the phenazopyridine arm will be given a 200 mg pill with a sip of water in the pre-operative area 1 hour before their scheduled procedure. Cystoscopy will be performed in the standard fashion during the course of the operation.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>sodium fluorescein</intervention_name>
    <arm_group_label>Sodium Fluorescein</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>phenazopyridine</intervention_name>
    <arm_group_label>oral phenazopyridine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  - Patients must be 18 years or older as well as willing and able to provide informed
             consent

          -  Patients undergoing a scheduled gynecologic procedure with cystoscopy

        Exclusion Criteria:

          -  - Patients are younger than 18 years

          -  Patients are unable or unwilling to provide informed consent

          -  Patients with a history of an allergic reaction to sodium fluorescein or
             phenazopyridine

          -  Patients with a history of renal insufficiency

          -  Patients with a history of liver disease

          -  Patients with a history of sickle cell disease

          -  Patients with a history of glucose-6-phosphate dehydrogenase deficiency

          -  Patients with a history of chronic obstructive pulmonary disease or currently being
             treated for asthma
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>David Sheyn, MD</last_name>
    <phone>216-844-1035</phone>
    <email>david.sheyn@uhhospitals.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>University Hospitals Cleveland Medical Center</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44106</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>David Sheyn, MD</last_name>
      <phone>216-844-3896</phone>
      <email>david.sheyn@uhhospitals.org</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 27, 2016</study_first_submitted>
  <study_first_submitted_qc>April 28, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 2, 2016</study_first_posted>
  <last_update_submitted>May 5, 2017</last_update_submitted>
  <last_update_submitted_qc>May 5, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">May 9, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University Hospitals Cleveland Medical Center</investigator_affiliation>
    <investigator_full_name>David Sheyn</investigator_full_name>
    <investigator_title>Physician</investigator_title>
  </responsible_party>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

